Every S-3 that Dogwood Therapeutics, Inc. (DWTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow DWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DWTX filings page.
Dogwood Therapeutics, Inc. filed a Form S-3 to register up to 6,433,126 shares of common stock for resale by existing investors, rather than to issue new shares. The shares come from pre-funded warrants with a $0.0001 exercise price and common stock warrants with a $3.28 exercise price that were previously issued to a single institutional investor.
Dogwood will not receive any proceeds from sales of these registered shares, though it could receive cash if any unexercised warrants are exercised. As of January 14, 2026, the company had 32,082,464 shares outstanding, which would rise to 38,515,590 if all related warrants were exercised, and the filing warns that this could substantially dilute existing holders and pressure the share price.
The company is a pre-revenue, development-stage biopharmaceutical business developing Halneuron for cancer and chemotherapy-induced pain and antiviral combinations IMC-1 and IMC-2 for fibromyalgia and Long-COVID. Dogwood estimates Q4 2025 operating expenses of about $3.9 million and cash and equivalents of about $6.5 million as of December 31, 2025, and its auditor’s 2024 report includes a going concern explanatory paragraph.
Dogwood Therapeutics, Inc. filed an S-3/A registering the resale of up to 28,038,689 shares of Common Stock that may be sold from time to time by named selling stockholders. The company is not selling any shares and will not receive proceeds from these resales.
The registered shares include stock issued in prior transactions and shares underlying Series A, A-1 and A-2 non-voting convertible preferred stock, each convertible into 10,000 common shares upon required stockholder approvals. The filing notes that conversion of each preferred series requires stockholder approval. As of October 16, 2025, shares outstanding were 2,293,162. The prospectus states this offering itself will not increase outstanding shares unless conversions occur.
Holders may sell at their discretion under the plan of distribution. Examples include Sealbond Limited 21,822,333 and Conjoint Inc. 2,842,638. The company remains an emerging growth and smaller reporting company, with Common Stock listed on Nasdaq as “DWTX.”
Dogwood Therapeutics, Inc. has filed a shelf registration on Form S-3 to register resale of shares under a prospectus that covers Common Stock and multiple series of Preferred Stock. The prospectus states 43,000,000 shares of Common Stock and 2,000,000 shares of preferred stock authorized, including specific Series allocations for Series A, A-1 and A-2. The document identifies named selling stockholders and discloses that percentages are based on 2,293,162 shares of Common Stock outstanding as of September 30, 2025. The prospectus incorporates recent SEC filings by reference, including the 2024 Form 10-K and multiple 10-Qs and 8-Ks filed in 2025, and includes customary undertakings regarding post-effective amendments, prospectus use and liability. The registration statement lists exhibits such as Certificates of Designation for the preferred series, legal opinions, accountant consents and powers of attorney and is signed by the CEO, CFO and members of the board.